<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370681</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_VCM_102</org_study_id>
    <nct_id>NCT01370681</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of CJ30001 and HKB0701/SLM0807 in Healthy Subject</brief_title>
  <official_title>An Open-label, Randomized, Crossover Study to Evaluate the Pharmacokinetics After Administration of CJ30001 and Co-administration of HKB0701/SLM0807 in Korean Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to demonstrate the bioequivalence of CJ30001(fixed-dose
      combination tablet of HKB0701 and SLM0807) relative to HKB0701 and SLM0807 co-administered to
      healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric mean Cmax</measure>
    <time_frame>up to 24hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean AUCt</measure>
    <time_frame>up to 24hrs</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Period I : HKB0701 and SLM0807, Period II : CJ30001</intervention_name>
    <arm_group_label>Group1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Period I : CJ30001, Period II : HKB0701 and SLM0807</intervention_name>
    <arm_group_label>Group2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers who are in age range of 20-50years and the weight range is not
             exceed Â±20% of ideal weight. Ideal weight = [height -100]*0.9

          -  Subjects with no history of any significant chronic disease

          -  Judged to be in good health on the basis of their vital sign, ECG, physical exam and
             routine laboratory data

          -  Available for the entire study period

          -  Willing to adhere to protocol requirements and sign a informed consent form

        Exclusion Criteria:

          -  Subjects who have taken any drugs to induce or inhibit hepatic enzyme activity within
             30days prior to drug administration

          -  Subjects who have symptom of an acute illness within 4 weeks prior to drug
             administration

          -  Subjects with a history of clinically significant allergies including drug allergies

          -  Subjects whose clinical laboratory test values are outside the accepted normal
             range(Especially,AST or ALT &gt;1.25 times to normal range or total bilirubin &gt; 1.5times
             to normal range)

          -  Subjects with a history of drug, caffeine abuse(caffeine drink &gt;5cups/day)

          -  Subjects with a history of alcohol abuse(alcohol&gt;30g/day) or who have ever drinked
             alcohol whinin 7days prior to drug administration

          -  Heavy smoker ( &gt;10cigarettes/day)

          -  Subjects who have had a diet known to interfere with the absorption, distribution,
             metabolism or excretion of drugs (especially, consumption of grapefruit juice)

          -  Subjects who have donated plasma within 60days prior to drug administration

          -  Subjects who have participated in a clinical study within 90days prior to drug
             administration

          -  Subjects who have received any drugs that might confound the results of the trial in
             the opinion of principal investigator within 10days prior to drug administration
             (cimetidine within 7days prior to drug administration)

          -  Female subjects who are pregnant, breastfeeding or not using medically acceptable
             birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Gook Shin, MD, ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <last_update_submitted>June 9, 2011</last_update_submitted>
  <last_update_submitted_qc>June 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Geun Seog, Song / Director of Regulatory and Clinical Development</name_title>
    <organization>CJ Cheiljedang Corporation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

